September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Topical Administration of Somatostatin to An Oxygen-Induced Retinopathy (OIR) Model of Retinopathy of Prematurity (ROP)
Author Affiliations & Notes
  • Hamzah Khalaf
    Ophthalmology, SUMMA Health System, Kent, Ohio, United States
  • Jeffrey Dunmire
    Ophthalmology, SUMMA Health System, Kent, Ohio, United States
  • Richard W Hertle
    Vision Center, Akron Children's Hspital, Akron, Ohio, United States
    Ophthalmology, SUMMA Health System, Kent, Ohio, United States
  • Berta Ponsati
    BCN Peptides S.A, Barcelona, Spain
  • Jimena Fernandez
    BCN Peptides S.A, Barcelona, Spain
  • Lluis Riera-Sans
    BCN Peptides S.A, Barcelona, Spain
  • Rachida Bouhenni
    Ophthalmology, SUMMA Health System, Kent, Ohio, United States
  • Footnotes
    Commercial Relationships   Hamzah Khalaf, None; Jeffrey Dunmire, None; Richard Hertle, None; Berta Ponsati, BCN Peptides (E); Jimena Fernandez, BCN Peptides (E); Lluis Riera-Sans, BCN Peptides (E); Rachida Bouhenni, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 6259. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Hamzah Khalaf, Jeffrey Dunmire, Richard W Hertle, Berta Ponsati, Jimena Fernandez, Lluis Riera-Sans, Rachida Bouhenni; Topical Administration of Somatostatin to An Oxygen-Induced Retinopathy (OIR) Model of Retinopathy of Prematurity (ROP). Invest. Ophthalmol. Vis. Sci. 2016;57(12):6259.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Currently, treatments for retinopathy of prematurity (ROP) are invasive and while topical applications for retinal delivery of medications have been successfully developed, there are none that have been shown to treat ROP. In this pilot study, we used an Oxygen-Induced Retinopathy (OIR) mouse model of ROP to test the efficacy of topical somatostatin in reducing retinal neovascularization, an approach that was proven effective in prevention of diabetic retinopathy in animal studies and is now undergoing human trials.

Methods : Neonatal mice (C57BL/6, n=9) were exposed to 75% oxygen from postnatal day (P)7 until P12 and returned to room air (21% oxygen). Somatostatin (0.1%, n=3 and 1.0%, n=3) or vehicle (n=3) was administered once daily to both eyes from P12 to P17. Mice with body weight less than 6g at P17 were excluded. Following enucleation on P17, whole retinas were dissected, mounted, and stained with isolectin. The degree of vascular proliferation was examined by blinded observers using a fluorescent microscope and scored according to a well described retinopathy scoring system which assessed number of tufts, vessel tortuosity, vasoconstriction, and retinal hemorrhage. The total retinopathy score was compared qualitatively.

Results : Retinal mounts from the somatostatin treated eyes showed reduced average total retinopathy score compared to those treated with vehicle (4.8 vs 6.0 respectively). In addition, the average total retinopathy score of the somatostatin 1.0% group was slightly reduced compared to that of the somatostatin 0.1% group (4.67 vs 5.0).

Conclusions : These results support the hypothesis that topical administration of somatostatin once daily may reduce neovascularization in the OIR mouse model. This proof-of-concept study paves the road to add novel, obviously advantageous, topical treatments for ROP. We are continuing this research by increasing the sample size in order to test our hypothesis in a more statistically rigorous fashion.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×